Disease · EFO_0006834

septic shock

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. septic shock. Diseases, record EFO_0006834. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0006834

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: septic shock; Open Targets
Open Targets ID: EFO_0006834; Open Targets
NCI Thesaurus: C35018; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 122 drugs, from DailyMed and FDA; Open Targets

Drugs122

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EPINEPHRINE	CHEMBL679	Small molecule	Approval	DailyMed	7	3	3	Drugs and targets
NALOXONE HYDROCHLORIDE	CHEMBL1718	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
ANGIOTENSIN II ACETATE	CHEMBL3989932	Protein	Approval	FDA	1	0	0	Drugs and targets
PHENYLEPHRINE HYDROCHLORIDE	CHEMBL1200339	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
HYDROCORTISONE	CHEMBL389621	Small molecule	Phase 3	ClinicalTrials.gov	34	34	34	Drugs and targets
NOREPINEPHRINE	CHEMBL1437	Small molecule	Phase 3	ClinicalTrials.gov	29	29	29	Drugs and targets
ASCORBIC ACID	CHEMBL196	Small molecule	Phase 3	ClinicalTrials.gov	23	23	13	Drugs and targets
THIAMINE	CHEMBL1588	Small molecule	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets
TERLIPRESSIN	CHEMBL2135460	Protein	Phase 3	ClinicalTrials.gov	18	18	18	Drugs and targets
METHYLENE BLUE	CHEMBL550495	Small molecule	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets

1 to 10 of 122

See all 122 drugs

Targets178

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	8	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 178

See all 178 targets

Trials237

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00604214	Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock	Phase 3	1,696	2012-09-18	Sepsis	DROTRECOGIN ALFA (ACTIVATED)	Its record names the disease	ClinicalTrials.gov
NCT02508649	Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial	Phase 2/3	868	2021-04-06	Septic Shock	SELEPRESSIN	Its record names the disease	ClinicalTrials.gov
NCT03869385	Albumin Replacement Therapy in Septic Shock	Phase 3	440	2024-10-28	Septic Shock	ALBUMIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT03085758	Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB	Phase 2	301	2021-03-24	Septic Shock	ENIBARCIMAB	Its record names the disease	ClinicalTrials.gov
NCT00604019	Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock	Phase 3	252	2012-12-07	Septic Shock	DOPAMINE, NOREPINEPHRINE	Its record names the disease	ClinicalTrials.gov
NCT01665092	Rapid Administration of Carnitine in sEpsis	Phase 2	250	2019-06-04	Septic Shock	LEVOCARNITINE	Its record names the disease	ClinicalTrials.gov
NCT03389555	Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial	Phase 2/3	205	2021-01-29	Sepsis, Septic Shock, Metabolic Disturbance	ASCORBIC ACID, HYDROCORTISONE, THIAMINE	Its record names the disease	ClinicalTrials.gov
NCT03338569	Vitamin C and Septic Shock	Phase 2/3	125	2021-07-14	Septic Shock, Sepsis	ASCORBIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02580240	Initiation of Hydrocortisone for the Treatment of Septic Shock	Not applicable	118	2017-08-07	Septic Shock	HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov
NCT03550794	Thiamine as a Renal Protective Agent in Septic Shock	Phase 2	95	2023-06-27	Sepsis, Kidney Injury, Thiamine Deficiency	THIAMINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 237

See all 237 trials

Comparisons in its trials52

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Drotrecogin Alfa (Activated) vs Placebo: serious adverse events	119 of 833	96 of 833	1,666	NCT00604214	Trial comparisons
Albumin Group vs Control Group Without Albumin:: deaths from any cause	91 of 222	96 of 218	440	NCT03869385	Trial comparisons
Albumin Group vs Control Group Without Albumin:: serious adverse events	3 of 222	2 of 218	440	NCT03869385	Trial comparisons
Albumin Group vs Control Group Without Albumin:: 28-day Mortality	66 of 213	80 of 210	423	NCT03869385	Trial comparisons
Albumin Group vs Control Group Without Albumin:: 60-day Mortality	82 of 211	95 of 210	421	NCT03869385	Trial comparisons
Albumin Group vs Control Group Without Albumin:: 90-day All Cause Mortality	91 of 210	96 of 209	419	NCT03869385	Trial comparisons
Dopamine vs Norepinephrine: Efficacy and Safety of Dopamine Versus Norepinephrine in Septic Shock	67 of 134	51 of 118	252	NCT00604019	Trial comparisons
Dopamine vs Norepinephrine: serious adverse events	0 of 134	0 of 118	252	NCT00604019	Trial comparisons
Vitamin C, Vitamin B1, Corticosteroids vs Placebo: Intensive Care Unit (ICU) Mortality	23 of 101	20 of 99	200	NCT03389555	Trial comparisons
Vitamin C, Vitamin B1, Corticosteroids vs Placebo: 30-day Mortality	35 of 101	29 of 99	200	NCT03389555	Trial comparisons

1 to 10 of 52

See all 52 comparisons in its trials

Papers from its trials234

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42573415	RESULT	1	PubMed
40019329	RESULT	1	PubMed
40009025	RESULT	1	PubMed
38392609	RESULT	1	PubMed
38003863	RESULT	1	PubMed
37510705	RESULT	1	PubMed
36915146	RESULT	2	PubMed
36705345	RESULT	1	PubMed
36507525	RESULT	1	PubMed
36505110	RESULT	1	PubMed

1 to 10 of 234

See all 234 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0006834

GET https://conductscience.org/api/diseases/v1/EFO_0006834/drugs?page=2

API reference For AI assistants